



FOR IMMEDIATE RELEASE

SynapDx Corporation Raises \$9 Million in Series A Funding
Company to Develop Proprietary Technologies for the Early Detection of Autism

June 1, 2010: Waltham, MA: SynapDx Corp., a new company focused on developing and commercializing diagnostic testing for the early detection of autism, announced the completion of a \$9 million Series A financing by Bain Capital Ventures, General Catalyst Partners, and North Bridge Venture Partners.

"Autism has a profound effect on children and their families," said Stanley N. Lapidus, the company's founder, President and Chief Executive Officer. "The right objective blood-based diagnostic test for autism may help achieve earlier diagnosis, more rapid intervention, and improved outcomes."

About SynapDx Corporation

SynapDx was formed to develop and commercialize blood-based diagnostic tests for the early detection of autism. SynapDx was founded by Stanley N. Lapidus, an experienced life-sciences entrepreneur and inventor with 31 issued patents. Mr. Lapidus founded and led Cytoc Corp., EXACT Sciences Corp., and Helicos BioSciences Corp. Mr. Lapidus' co-founders of SynapDx Corp. include Jeffrey R. Lubner, Esq. and Patrick A. Anquetil, PhD. For more information, please visit: www.synapdx.com.

Contact:

SynapDx Corporation
Theresa Tribble
Senior Director of Clinical Market Development
508.485.5820
info@synapdx.com

- ### -